Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1957 2
1958 1
1963 1
1969 1
1975 2
1976 1
1977 3
1980 3
1982 1
1983 1
1986 1
1987 6
1988 1
1989 6
1991 1
1992 1
1993 3
1994 5
1995 4
1996 2
1997 4
1999 2
2000 6
2001 3
2003 6
2004 2
2005 3
2006 5
2007 2
2008 4
2009 2
2010 6
2011 7
2012 10
2013 8
2014 11
2015 7
2016 5
2017 2
2018 5
2019 2
2020 1
2021 5
2022 8
2023 5
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
Liraglutide-Induced Hepatotoxicity.
Maor Y, Ergaz D, Malnick SDH, Melzer E, Neuman MG. Maor Y, et al. Among authors: melzer e. Biomedicines. 2021 Jan 22;9(2):106. doi: 10.3390/biomedicines9020106. Biomedicines. 2021. PMID: 33498980 Free PMC article.
Alcoholic Liver Disease: Role of Cytokines.
Neuman MG, Maor Y, Nanau RM, Melzer E, Mell H, Opris M, Cohen L, Malnick S. Neuman MG, et al. Among authors: melzer e. Biomolecules. 2015 Aug 28;5(3):2023-34. doi: 10.3390/biom5032023. Biomolecules. 2015. PMID: 26343741 Free PMC article. Review.
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles RA, Aaronson NK. Bancroft EK, et al. BJU Int. 2024 Sep;134(3):484-500. doi: 10.1111/bju.16432. Epub 2024 Jun 5. BJU Int. 2024. PMID: 38839570 Free article.
Helicobacter pylori: friend or foe?
Malnick SD, Melzer E, Attali M, Duek G, Yahav J. Malnick SD, et al. Among authors: melzer e. World J Gastroenterol. 2014 Jul 21;20(27):8979-85. doi: 10.3748/wjg.v20.i27.8979. World J Gastroenterol. 2014. PMID: 25083071 Free PMC article. Review.
1-Methyl-2-(4-methyl-phen-yl)-4-morpholinopyridazine-3,6(1H,2H)-dione.
Gzella A, Melzer E, Kaczmarek MS, Woźniak Z. Gzella A, et al. Among authors: melzer e. Acta Crystallogr Sect E Struct Rep Online. 2008 Jan 11;64(Pt 2):o435. doi: 10.1107/S1600536808000111. Acta Crystallogr Sect E Struct Rep Online. 2008. PMID: 21201462 Free PMC article.
159 results